The hottest film recently should be "I'm not a god of medicine". I won't comment on the film for the time being. Instead, the drug prototype Gleevec, that is, imatinib, and the field of small molecule targeted drug R&D and manufacturing, which are cited in the film, have a lot of roots with BPI.

“Decades of research has led to the birth of the first small molecule targeted drug Gleevec (Imatinib)”

From the discovery of Philadelphia chromosome in 1960 to the approval of imatinib by FDA in 2001, Gleevec has achieved more than ten academicians of the American Academy of Sciences, saved countless CML patients struggling with life and death, and opened a new chapter of tyrosine kinase inhibitor small molecule targeted drugs……

（Pictures from the Internet）

As of 2017, more than 40 kinds of drugs in the world have been approved by FDA, and more than 100 drug molecules are under clinical research. In China, there are 20 kinds of drugs approved by CFDA.

（Pictures from the Internet）

“BPI: I'm not a god of medicine, but I've been in the field of antitumor drugs for 15 years”

When it comes to small molecule targeted drugs, we have to mention BPI. Since its inception, BPI has developed more than 30 anti-tumor generic drugs, including tyrosine kinase inhibitors, relying on scientific research institutions such as the Institute of medicine of the Chinese Academy of Sciences. After 15 years of precipitation and development, from the laboratory to the market, from only providing primary technical services for pharmaceutical manufacturers at home and abroad to providing raw drug varieties and industrial solutions supporting preparations for global anti-cancer drug pharmaceutical enterprises, we have been committed to the research and production of anti-tumor drug raw materials for more than ten years.

Taking chemical synthesis technology as the starting point, cooperate with modern production and manufacturing equipment to develop and manufacture high-quality advanced intermediates of antitumor APIs. BPI has established a stable cooperative production mode with factories with cGMP and approved by FDA, and acquired a stable production base with high-end API manufacturing potential at the same time. At the beginning of this year, with the capital injection of the listed company Jianfeng group, Anhui Biocompounds Pharmaceutical Co., Ltd. was established to build a small molecule targeted drug manufacturing base, establish a complete production quality system with safe production, cleaner production and efficient production as the core, and provide customers with stable and reliable products with renewable warranty.

manufacturing base→

“Return to the Chinese market from the Indian market and make a modest contribution to the field of generic drugs in China.”

Since the establishment of BPI in 2003, the company has made great efforts to develop synthetic process technology research and quality research. It not only starts from the chemical mechanism, but also cooperates with the comprehensive utilization of equipment, so as to realize clean, sustainable and safe production while reducing costs and improving product quality. BPI aims to improve the quality standards of the industry in order to have a great impact on the long-term development and brand competitiveness of pharmaceutical companies.

At the beginning of its founding, like many domestic intermediate manufacturers, its products were mainly sold to foreign generic drug markets, such as India and the European Union, with a product share of more than two-thirds. India, where the story of "I am not a god of medicine" took place, was once the most important market for BPIDomestic pharmaceutical companies do not pay much attention to such products. However, it is gratifying that in the past decade, there has been an unprecedented upsurge in the research and development of antitumor drugs in China. The number of new drugs such as me too, me better and even first online drugs have increased exponentially, and the number of generic drugs for approval has also increased sharply. At this stage, BPI gradually shifted its focus to the domestic market, and gradually cooperated with domestic top pharmaceutical companies through all-round research on product quality and strict process. Through a complete document system, detailed quality research, standardized design of R & D and production process, and the establishment of certification production system, BPI provides dozens of major pharmaceutical factories in China with intermediates and technical services of original new drugs and first generic drugs, and strives to make a modest contribution to the development of anti-tumor generic drugs and even new drugs in China.

* Business throughout the country.

* Manufacturing plants are distributed in four provinces.

Business distribution

“Preliminary establishment of small molecule targeted drug imitation platform”

After 15 years of precipitation, the company has accumulated a lot. Through the integration of technology, manufacturing and market resources, BPI's strategy of establishing a small molecule targeted drug imitation platform has been preliminarily realized. In the next few years, BPI plans to build more than 200 mu of GMP compliant production base in Anhui factory, and plans to declare more than 20 small molecule targeted APIs and their key raw materials and intermediates.

At present, the anti-tumor varieties of BPI have covered most tyrosine kinase products, including generic drugs and domestic first-class new drugs. BPI is willing to work with major pharmaceutical companies to jointly develop, produce and sell all kinds of APIs and intermediates of divine drugs, so as to contribute to the field of antitumor drugs in China.